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Semisynthetic and Natural Product
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Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen,
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The 1940s and 1950s witnessed a diverse search for not just natural product antibiotics
but also for synthetic and semisynthetic compounds. This review revisits this epoch,
using the research by a Danish pharmaceutical company, LEO Pharma, as an example.
LEO adopted a strategy searching for synthetic antibiotics toward specific bacterial
pathogens, in particular Mycobacterium tuberculosis, leading to the discovery of a
new derivative of a known drug. Work on penicillin during and after WWII lead to the
development of associated salts/esters and a search for new natural product antibiotics.
This led initially to no new, marketable compounds, but concluded with the serendipitous
discovery of fusidic acid, an antibiotic used to treat infections by Staphylococcus aureus,
in 1960. The discovery process included contemporary approaches such as open
innovation; targeting specific pathogens and/or specific organs in the patient; examining
the effects of antimicrobial compounds on bacterial virulence as well as on antibiotic-
resistant variants, and searching for antibiotic producers among microorganisms not
previously well explored. These activities were promoted by the collaboration with a
renowned Danish clinical microbiologist, K. A. Jensen, as well as company expertise in
fermentation technologies, chemical synthesis and purification of bioactive compounds
from organic materials.
Keywords: antibiotic, antimicrobial compound, LEO Pharma, screening, tuberculosis
INTRODUCTION
This review covers the 1940s and 1950s that witnessed the golden age of discoveries of
naturally occurring antibiotics (Table 1), with the American pharmaceutical industry as a major
player (Anon, 1958; McGraw, 1976; Temin, 1979; Greenwood, 2008). The American natural
product antibiotic manufacturers at the time included Abbott, American Cyanamid (Lederle),
American Home Products, Bristol-Myers, Commercial Solvents Corporation, Eli Lilly, Merck, Olin
Mathieson, Parke-Davis, Penick, Pfizer, and Upjohn (Anon, 1958). They represented a mixture
of holding-operating and pharmaceutical companies, all with a diversified line of pharmaceutical
products. Large-scale empirical screening programs for natural product antibiotics constituted an
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TABLE 1 | Discovery milestones of synthetic and natural product antibiotics
1943–1960, with indication of application toward tuberculosis.
Product class/compound (example) Application Discoverya
Para-aminosalicylic acid (PAS) Tuberculosis 1943 (s, i/p)
Aminoglycosides (streptomycin) Tuberculosis 1943 (n, p)
Cyclopeptides (bacitracin) 1943 (n, p)
Thiosemicarbazone (thiacetazone) Tuberculosis 1944 (s, i)
Nitrofurans (nitrofurantoin) 1944 (s, i)
Cephalosporins 1945 (n, p)
Chloramphenicols (chloramphenicol) 1945 (n, i)
Tetracyclines (chlortetracycline) 1945 (n, i)
Cyclopeptides (polymyxins) 1946 (n, i)
Diaminopyrimidines (trimethoprim) 1947/1956b (s, i)
Macrolides (erythromycin) 1942/1950b (n, i/p)
Isoniazid Tuberculosis Around 1950 (s, i)
Pleurimutilin 1951 (n, p)
Nicotinamide derivative (Pyrazinamide) Tuberculosis 1952 (s, i)
Streptogramins 1953 (n, i)
Glycopeptides (vancomycin) 1953 (n, i)
Nitroimidazoles (metronidazole) 1953/1957b (n/s, i/p)
Cycloserine Tuberculosis 1954 (n, i)
Aminocoumarin (novobiocin) 1955 (n, i)
Rifamycins Tuberculosis 1957 (n, i)
Fusidic acid 1960 (n, i)
Letters in bold indicate discovery by LEO. a Inconsistencies were noted among
sources regarding years recorded for discoveries. Data are primarily from
Greenwood, 2008 but also from Kavanagh et al., 1951; McGraw, 1976; Silver,
2011; Lewis, 2013; and Genilloud, 2014. n, natural product antibiotic; s, synthetic
antibiotic; i, first compound was discovered in an industrial laboratory; p, first
compound was discovered in a laboratory belonging to a public institution. bYear
indicate discovery of compound listed as example.
important activity for several of these companies at the time,
but for some of them empirical searches were a temporary
aberration from research based on synthetic organic chemistry
(Daemmrich, 2009).
The discovery approach for naturally occurring antibiotics was
simple and consisted of screening primarily soil microorganisms
on a range of agar media for antagonism toward selected target
organisms: the Waksman platform (Aminov, 2010; Lewis, 2013;
Wright, 2014; Katz and Baltz, 2016), although screenings with
liquid cultures were preferred by Eli Lilly from the early 1950s
(McGraw, 1976). Such empirical screenings involved compounds
whose molecular nature was unknown at the time of discovery,
and their subsequent purification, structural characterization and
studies of the mode of action were frequently a challenging
process. Deciding whether a screening had exhausted the
possibilities, likely depended on the moment when the cost of
failures and false leads exceeded the limit of economical or
other constraints set by the company. Failures constituted a
common experience only now and then punctuated by the rare
discovery that lead to the marketing of a new product. One
publication from 1950 stated that “. . .the principal objective
is to differentiate between already known antibiotics, which
are of but little interest, and new antibiotics which are of
little interest, and new antibiotics which might find usefulness
in chemotherapy. In our experience most of the antibiotic-
producing soil organisms which survive the initial bacteriological
screening are eliminated here. . .after screening several hundred
thousand soil microorganisms, one is unusually fortunate if one
or two organisms continue to be of interest” (Kane et al., 1950).
Even so, an optimistic approach frequently prevailed:
“Everywhere the searchers say: ‘If it can happen once, surely
it can happen again”’ (Raper, 1952). Greenwood (2008) also
mentions “the intense excitement of the time” (p. 225), and
R. G. Benedict who was involved in an antibiotic discovery
program at Northern Regional Research Laboratory at Illinois,
noted that “the discovery of these agents has stimulated the
hope that other antagonistic strains, yet undiscovered among the
actinomycetes, may provide additional useful tools” (Benedict,
1953). Figure 1 illustrates the high degree of discoveries up
to 1965 of novel compounds within this area as well as the
high proportion of cases with described chemical compositions
or structures. From the 1960s, it became apparent that the
possibilities for finding new marketable compounds by the
Waksman platform were exhausted. The low hanging fruits
were gone (Quinn, 2009; Greenwood, 2008; Silver, 2011; Lewis,
2013, 2015; Wright, 2014). Empirical screenings for such
compounds still have relevance today, as many of the initial
shortcomings have been addressed. These shortcomings include
risk of rediscovery, antibiotic resistance, lack of methodology
for cultivating antibiotic-producing bacteria, maintaining their
stability for antibiotic production, complex chemical structures,
and labilities of compounds that required specialized equipment
and expertise for purification and characterization (Peláez, 2006;
Aminov, 2010,2017; Silver, 2011; Lewis, 2013,2015; Genilloud,
2014; Spellberg, 2014; Wright, 2014; Katz and Baltz, 2016;
Abouelhassan et al., 2019). Regarding antibiotic resistance the
range of times between introduction and the first observation of
resistance varied from almost immediately, as was the case for
penicillinase-resistant Staphylococcus aureus while in other cases
such as vancomycin resistance in enterococci it took several years
(Silver, 2011). Interestingly, the presence of antibiotic-resistant
S. aureus in hospital environments was a driver for searching
for new antibiotics already in the early 1950s (McGraw, 1976;
Gradmann, 2016). This issue became even more important later
on with the introduction in the 1960s of semisynthetic penicillins
not susceptible to penicillinases as an example (Greenwood, 2008;
Aminov, 2010; Gradmann, 2016).
During the 1930s and early 1940s, the pharmaceutical industry
synthesized sulfonamides and sulfones to obtain compounds
with improved antimicrobial, pharmacological and toxicological
characteristics. These examples on synthetic antibiotics (organic
structures synthesized in the laboratory) included more than
5000 sulfonamide derivatives by the end of WWII (Greenwood,
2008). After WWII, the pharmaceutical industry continued
research on synthetic compounds with anti-tuberculosis drugs
constituting a substantial part of these activities. This bacterium
is difficult to treat due to the permeability barrier presented
by its cell envelope, and the nature of the complex lesions
in infected patients (Tanner et al., 2018). Further, tuberculosis
requires prolonged multi-drug treatment to prevent treatment
failure due to the emergence of resistance. This resistance was
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FIGURE 1 | Discoveries of new natural product antibiotics produced by actinomycetes 1940–1965 (data from Waksman and Lechevalier, 1953 and Umezawa et al.,
1967) and numbers of actinomycetes antibiotics available on the American market during the late 1940s-early 1950s (data from Anon, 1958).
in the 1940s and 1950s to a higher degree linked to individual
patients rather than a result of being spread within populations
as has been the case for multi-drug resistant strains during the
1980s and 1990s (Keshavjee and Farmer, 2012; Gradmann, 2016,
Fox et al., 2017). As for penicillin-resistant S. aureus variants, this
situation led to searches during the 1940s and 1950s for new drugs
that resulted in discoveries of synthetic compounds targeting the
tuberculosis bacterium (Table 1). The introduction of synthetic
compounds against other bacterial pathogens also took place
during this time (Table 1; Greenwood, 2008; Wright et al., 2014).
In contrast to natural product antibiotics, the known chemical
structures of synthetic antibiotics made it possible in some cases
to predict, whether a specific synthetic approach would lead to
the desired result. One example is a research summary of work
done from 1943 to 1953 at the company that constitutes the focus
of this study, LEO Pharma. It was noted how many synthetic
compounds within a given category, it would be reasonable to
synthesize to ensure with an acceptable degree of accuracy that
no active compounds were left untested1.
Chemical synthesis of naturally occurring antibiotics turned,
on the other hand, out to be too difficult or expensive in most
cases with chloramphenicol as the prominent exception. Instead,
there are examples early on of the development of derivatives of
natural fermentation products (semisynthetic antibiotics) such as
dihydrostreptomycin and tetracycline. Overall, the value of semi-
synthetic antibiotics was recognized from the work on β-lactams
at the end of the 1950s.
I illustrate the work done on antibiotics in the 1940s and
1950s by examining one particular example: the research done
by the small Danish company LEO Pharma. This company
manufactured at that time several different drugs, many of
them belonging to other categories than antibiotics. The
company was active in research and development of natural
1Report to management committee from Chemical Research Laboratory,
December 1st, 1953.
product, synthetic and semisynthetic antibiotics frequently in
close collaboration with an internationally renowned medical
microbiologist (K. A. Jensen) with strategies depending to
a large degree on target species and pharmaceutic issues.
K. A. Jensen was involved in the first result from the
empirical search for natural product antibiotics: the re-
isolation of penicillin during WWII. Subsequent screening for
naturally-occurring compounds with its failures and ultimate
success was more a company activity that only initially
involved another external collaborator in a supportive role. The
work by LEO focused also on challenges such as antibiotic
resistance and targeting virulence properties of bacterial targets,
a potentially important strategy to counteract selection for
resistance. Finally, it is of interest how LEO supported the
innovation pipeline, by applying the open-source approach and
searching for new natural product antibiotics among poorly
investigated microorganisms.
The material for this review comes from different sources.
The scientific literature offered substantial information, including
quantitative data for discovery rates for actinomycetes antibiotics
1940–1965 obtained from Umezawa et al. (1967) and Waksman
and Lechevalier (1953) (see Supplementary Appendix S1 for
details). I have preferred to use the non-taxonomic term
actinomycetes (covering the important genus Streptomyces) due
to it has been used in a number of sources I quote. The
primary source material on antibiotic research from 1940 to
1960 is in the archive of LEO Pharma Historical Archives and
Museum. My manual search of this archive, across numerous
visits, was essential to the completion of this review. This archive
supplied meeting memos and summaries, letters and research
reports, timesheets for chemists 1946–1959, two hand-written
laboratory notebooks for the period from 1951 to 1956, orders for
target strains for screenings and lists outlining the contemporary
organization of the company into research units. Finally, I
interviewed a researcher who was involved in the discovery of
fusidic acid at LEO.
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OVERVIEW OF LEO PHARMA’S
RESEARCH AND PRODUCT PORTFOLIO
The purchase of a pharmacy store in 1908 marks the
beginning of the company. In 1909, LEO started production
of a yoghurt preparation, and marketed an aspirin product
soon thereafter. Then, in 1917 was launched the first Danish
export drug, Digisolvin, a standardized Digitalis-based product.
Hormones became a part of the product portfolio from
the 1920s (Schrøder, 2005; Schrøder et al., 2008). During
the 1940s and 1950s, the company maintained a broad
portfolio of products of which several were generics (Loldrup,
2014)2. Examples include anesthetics (e.g., Citodan 1939–
1956, Leostesin 1954–1988), diuretics (e.g., Diuregan 1929–
1957, Diural 1937–1945, Rontyl 1958–1996) and hormones (e.g.,
Delcortol 1957–1996, Heparin from 1940, Solvisat 1957–1976,
Testex 1937–1973) in addition to antibiotics. The company also
worked on several smaller development projects and product
categories. The majority of drugs were synthetic compounds
whereas the hormones constituted natural compounds extracted
from animal tissues or human urine. The know-how in
natural product chemistry obtained by working with hormones
proved important concerning subsequent purification of natural
product antibiotics.
Work done by the chemical laboratory of the company from
1943 to 1953 indicated an increase in ambitions as activities
changed from mostly working on drugs new to the Danish
market, but well known from the literature, to rely on original
research on a wide range of new drugs including antibiotics.
In 1953 only one technician and one chemist out of six and
seven, respectively, in that laboratory worked on the synthesis
of a known compound with known effects while the remaining
all carried out original work3. From 1946 to 1959, around
50% of research time was devoted to antimicrobial compounds
(Table 2). This research focused on penicillin salts and esters
and synthetic anti-tuberculosis compounds whereas research on
new, unknown natural product antibiotics only amounted to
2Note 1, monthly time allocation on subjects the chemists in the chemical research
laboratory worked on from 1947 to 1959 and an overview of research programs
from March 30th, 1953.
3See note 1.
minor amounts of research time (Table 2 and Figure 2). To this
effort, however, should be added time spent on screening and
characterizing antibiotic-producing microbial cultures by other
departments and laboratories within the company than those that
employed the chemists and for which there are no quantitative
data. Figure 3 presents timelines for work by the company on
the different categories of antibiotics. The company was active
in the field of antibiotics until the 1980s. Attention then turned
toward dermatological products that have remained the core area
of business for the company up to this day.
WORK AT LEO ON SYNTHETIC AND
SEMISYNTHETIC ANTIBIOTICS
1940–1960
The company collaborated from the 1930s with the medical
bacteriologist, Kai Adolf (KA) Jensen (1971) on synthesis
and testing of chemotherapeutics toward tuberculosis. Jensen
was an internationally renowned researcher on this disease in
addition to the chemotherapeutical application of antimicrobial
compounds. He was associated with the State Serum Institute
in Copenhagen until 1940 when he became a professor at the
Department of General Pathology, University of Copenhagen.
One of his research programs focused on selecting comparatively
simple synthetic compounds on the basis of a literature search
and subsequent synthesis of derivatives on a rational basis
to examine their chemotherapeutic effect toward tuberculosis4.
This collaboration continued during the 1940s and 1950s with
Jensen in multiple roles as consultant, performing tests of the
antimicrobial effects of compounds on laboratory animals and
in some cases also organizing clinical trials (Jensen, 1971, 2002;
Høiby, 2000, 2016). An example included a p-aminosalicylic acid
(PAS) derivative sent in 1954 to some Danish hospitals and
tuberculosis sanatoriums5.
The situation after WWII with tuberculosis on the rise
again in Europe, contributed to the urgency of the efforts as
was also the case for other pharmaceutical companies such
4Report from May 16th, 1952.
5Documented by several letters between LEO, medical doctors and K. A. Jensen.
TABLE 2 | Main programs and collaborators in antibiotic research programs at LEO 1946–1960.
Research program Collaborator % time of work by chemistsa Duration New lead compounds New derivatives
Penicillin salts/esters K. A. Jensen 26% 1946–1959 No Yes
Synthetic antibiotics towards tuberculosis K. A. Jensen 16% 1947–1958 No Yes
Other synthetic antibiotics K. A. Jensen 3% see Figure 2 No No
New natural product antibiotics H. L. Jensen 5% 1949–1956 No No
Fusidic acid No data 1960 Yes No
In total 50% 1946–1960 Yes Yes
aData were extracted from the monthly overviews on which subjects the chemists were working on. A total of 50% of the research time by chemists at the Chemical
Research Laboratory A (Chemical synthesis) and the Hormone Factory was spent on antibiotics. The remaining time was used on a variety of compounds targeting other
conditions than bacterial infectious diseases. The numbers do not give a precise impression on the overall work dedicated by the company to antibiotics as work in other
sections is not quantified. Research on penicillin manufacturing 1946–1949 is included in the percentage for penicillin salts/esters.
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FIGURE 2 | Overall numbers of chemists at the Chemical Research Laboratory A and the Hormone Factory and specific numbers of chemists working on various
categories of antibiotics at LEO from 1946 to 1959. In some cases, the workload by the individual chemist is not expressed as a whole number. This use of a
non-whole number is due to their time allocation among different projects, only some of which was concerning antibiotics. New antibiotics = New natural product
compounds.
FIGURE 3 | Timeline for the major activities within the antibiotic screening programs at LEO 1940–1960.
as Bayer in Germany (Gradmann, 2016)6. Developing new
antimicrobial compounds toward this disease constituted an
important activity at the company until the end of the 1950s
(Table 2 and Figures 2, 3)7. The company observed in 1949
that even after the introduction of streptomycin and PAS “a
really good chemotherapeutic agent was still lacking against
tuberculosis”8. The introduction of new methods in the form of
6Meeting summary September 7th, 1954.
7Document March 30th, 1953.
8Remarks regarding research on tuberculosis, Chemical Research Laboratory,
LEO, January 3rd, 1949.
improved growth media and new experimental animals allowed
more rapid test procedures. Further, a specific method, the
“object-glass method,” probably as described by Espersen (1949),
developed in Denmark and employed by LEO allowed an easy
way to determine whether a compound killed the tuberculosis
bacteria or only inhibited growth and, importantly, whether it
gave occasion for selection of resistant variants. In conclusion,
a combination of such methods gave LEO “a real chance
to direct the investigations toward a successful result”9. The
9See note 8. The object-glass method was mentioned in a discussion January 20th,
1954.
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objective was to examine all organic compounds in the company
chemical collection and to synthesize derivatives of various lead
compounds10. This amounted to around 500 compounds in 1956,
resulting in the discovery of a new p-aminosalicylic acid phenyl
ester (“Tebamin”; see below)11.
Specific examples of work on anti-tuberculosis compounds
included in 1943–1944 sulfonamides and sulfones and from 1950
to 1953 derivatives of known lead compounds including 53
derivatives of PAS (discovered in 1943, Table 1), 62 derivatives
of thiacetazone (discovered in 1944, Table 1) as well as
several isoniazid derivatives (discovered around 1950, Table 1)12.
Tuberculosis requires a long period of antibiotic treatment, which
increases the probability of selection of resistant variants. This
aspect had the attention of the scientific community already in
the late 1940s (Jain et al., 2008; Gradmann, 2016). LEO tested
some isoniazid derivatives toward isoniazid-resistant variants
of Mycobacterium tuberculosis showing the interest of LEO
on the issue of antimicrobial resistance13. LEO also researched
whether isoniazid and a related compound, nicotinamide
diminished the pathogenic potential of various bacterial target
organisms including Klebsiella pneumoniae, Salmonella, Shigella
and staphylococci in addition to Mycobacterium tuberculosis14.
This topic has gained recent attention, due to the hypothesis
that such an anti-virulence effect might not as rapidly lead
to antibiotic resistance as is the result of bacteriostatic or
bactericidal effects (Rasko and Sperandio, 2010; Wright, 2014;
Theuretzbacher and Piddock, 2019).
The company also aimed at synthesizing derivatives of anti-
tuberculosis compounds with an improved lung affinity, however,
these compounds showed too high toxicity15. Another line of
research, suggested by K. A. Jensen, focused on the effects of
serum binding on activity. Hydrazides and PAS derivatives were
of particular interest16. A PAS-derivative, p-aminosalicylic acid
phenyl ester (“Tebamin”) was developed with a less irritating
effect on patients than PAS and therefore suitable for the
long duration of chemotherapeutic treatment of tuberculosis
(Frederiksen et al., 1957; Tørning et al., 1958; Kingston, 2000;
Greenwood, 2008; Jain et al., 2008). This compound was on
the market from 1955 and up to 1973 and constituted the
most successful outcome of LEOs work on anti-tuberculosis
compounds (Jensen, 1971; Loldrup, 2014)17.
Chemical synthesis of antimicrobial compounds, many
generics, targeting other infectious diseases than tuberculosis
10Overview of work in the Chemical Research Laboratory, November 13th, 1950.
11Meeting summary with consultants September 5th, 1956.
12Note 1, report, November 20th, 1950 and meeting summary January 3rd,
1949. Information on sulfones (e.g., derivatives of 4,4′-diaminodifenylsulfone)
and sulfonamides (e.g., triphenylmethane sulfonamide) in letters June 9th, 1944
and June 19th, 1944. Work on thiosemicarbazones (concerning thiacetazone) is
illustrated by laboratory reports, e.g., for the period between January 15th and
April 15th, 1951.
13Meeting summaries October 9th 1954, February 14th, 1955, June 12th, 1957 and
August 15th, 1957.
14Meeting summary February 10th, 1955.
15See note 1.
16Meeting summaries July 22nd, 1954 and September 7th, 1954.
17Information on irritating effect is from meeting summaries January 10th 1955
and June 12th, 1957.
took place during the 1940s and 1950s. Three anti-syphilitic
agents were synthesized, and one of these was on the market from
1941 to 1953 (Loldrup, 2014)18. The antifungal effect of more than
200 compounds, including 50 new synthetic compounds were
examined between 1943 and 1953 but not resulting in new lead
compounds19. Sulfonamides constituted an area of much interest
in the early 1940s, with the synthesis of at least 30–40 derivatives
up to 1944. Some of these included known compounds (e.g.,
N′-dimethylacrylsulfanilamide) whereas others were new or with
unknown antimicrobial activities (e.g., sulfanilic acid hydrazide).
The compounds were, in collaboration with K. A. Jensen, tested
toward a panel of bacterial targets including anaerobic bacteria,
enterococci, E. coli, pneumococci, streptococci and “proteus
bacteria.” Some of the results appeared promising at first, but no
lead compounds were found20.
LEO did some limited research on semisynthetic derivatives
of chlortetracycline during 1953 and 195421. The archives do
not contain information on the objectives nor the outcome
of this research. Most likely, it was inspired, by the launch
by Pfizer in 1953 of tetracycline, a semisynthetic product
obtained by cleaving the carbon-chlorine bond of the natural
compound chlortetracycline (Greenwood, 2008; Wright et al.,
2014). Although a natural version of tetracycline was also
obtained around that time, the observation that it could be
made as a derivative of chlortetracycline demonstrated that
natural compounds could be perceived as starting points for
the semisynthetic discovery process (Wright et al., 2014). LEO
pursued this line of research further at the end of the 1950s
after the discovery by the United Kingdom Company, Beecham,
of a new way to produce semisynthetic penicillin derivatives
from 6-aminopenicillanic acid. LEO subsequently introduced the
semisynthetic mecillinam in 1972 (Greenwood, 2008). Ironically,
this research also initially led to the serendipitous discovery of
fusidic acid, a natural product antibiotic that became a highly
successful product for LEO from 1960 and onward.
THE SEARCH FOR NATURAL PRODUCT
ANTIBIOTICS AT LEO DURING THE
1940S AND EARLY 1950S
LEO’s involvement in the Danish efforts to develop an
independent production of penicillin during and after WWII
added research on natural product antibiotics to their activities.
The penicillin story started with the owner of LEO, Knud
Abildgaard (1901–1986) asking K. A. Jensen in 1942 whether he
would be interested in extending their collaboration to include
this topic. Jensen isolated the same year a penicillin-producing
18See note 2.
19See note 2.
20Note January 13th1942 on the application of sulfa drugs. Descriptions of specific
compounds were found in letters and reports between K. A. Jensen and LEO
June 9th, 1942: June 18th, 1942; September 30th, 1942; September 20th, 1943;
October 10th, 1943; October 16th, 1943; November 19th, 1943; December 6th,
1943; December 12th, 1943; January 20th, 1944; February 29th, 1944; May 15th,
1944; June 6th, 1944; August 14th, 1944, September 18th, 1944.
21Laboratory book 2, October 18th, 1951 to January 4th, 1956. See also note 1.
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mold from the air in his laboratory, similar to Fleming’s discovery
in 1928. LEO collaborated with K. A. Jensen on developing
the manufacturing process that went on in secrecy due to the
German occupation of Denmark during WWII (Jensen, 1971,
2002; Gotfredsen, 1991; Schrøder et al., 2008; Cozzoli, 2014;
Tjørnelund, 2016). The company undertook also screenings to
find penicillin-producing mold cultures22. Early on, it was clear
that it was not easy to synthesize penicillin G and the company
took a fermentative, not a chemical approach to manufacturing
(Tjørnelund, 2016). Producing penicillin in bulk by fermentation
became a success story for LEO that gave important know-
how for optimizing cultivation techniques for the production
of antibiotics and introduced the company as a pharmaceutical
player internationally.
During the late 1940s and 1950s there was an interest in
developing salts or esters of penicillin to overcome problems
of poor absorption and rapid excretion as well as to improve
organ affinity, such as for the lungs, whereas the activity of
the compound was unaltered (Greenwood, 2008). Fifty different
penicillin esters had been tested in collaboration with K. A.
Jensen by 1951, increasing to at least 75 different compounds in
1954 (Table 2 and Figures 2, 3)23. One outcome was Leocillin
(Benzylpenicillin, β-diethylaminoethyl ester hydrochloride) with
a high lung affinity that found application as a veterinary product
(Jensen et al., 1951; Schrøder, 2005). This compound was an
inspiration to LEO to search for anti-tuberculosis compounds
with similar affinities as mentioned previously24. Further work
also resulted in the successful marketing in 1956 of a calcium salt
of a variant of penicillin, V-penicillin in addition to an ampicillin
ester in 1967 and an esterified combination of ampicillin
and a beta-lactamase inhibitor in 1979 (Gotfredsen, 1999a,b;
Schrøder, 2005).
In contrast to the work on penicillin, K. A. Jensen was not
involved in the natural product antibiotic screening program.
Production of additional antibiotics, either known compounds
on license such as streptomycin or entirely new compounds,
would be an economic incentive to keep the penicillin production
plant at LEO busy25. The company was also aware of the
need to find new broad-spectrum chemotherapeutic compounds
with activity toward bacterial pathogens resistant to penicillin,
streptomycin and sulphonamides26. Most likely, M. tuberculosis
and S. aureus were among the pathogens that had the attention
in that regard. A letter from the head of the Bacteriological
Department at LEO to R. G. Benedict at the Northern Regional
Research Laboratory, U.S.A. stated that the company would
be interested in receiving bacterial strains resistant to various
known antibiotics. A draft list contained 30 species or types
with the expectation that the final version would include
around 50 species/types in addition to strains of rickettsia
22Report on work on new chemotherapeutics July 1st-July 31st, 1944.
23Documented by numerous laboratory and meeting reports.
24See note 1.
25Overview October 16th, 1952 on research tasks of the factory.
26Undated proposal for routine testing of substrate samples on pathogenic
bacteria, including 30 (unspecified) species and strains “that are not satisfactorily
treatable with penicillin, streptomycin or sulfonamides and which plays an
important role in human or veterinary pathology.”
bacteria and viruses. In 1950 or 1951, several strains including
two penicillin-resistant strains of Staphylococcus aureus and
Streptococcus pyogeneswere ordered from the National Collection
of Type Cultures in United Kingdom. and the American
Type Culture Collection as well as from the State Serum
Institute (Supplementary Table S1)27. This strategy resembled
the research leading to the discovery of neomycin in 1948/49 by
the Waksman laboratory and the research later done by Bayer
(Waksman and Lechevalier, 1949; Gradmann, 2016). Antibiotic-
resistant strains in the target panel would both work as a
dereplication technique to discard known antibiotics from the
search process and as a means to find new useful antibiotics
toward otherwise resistant target strains. The application of
antibiotics for veterinary use, as feed supplements or as anti-
cancer or anti-viral drugs presented additional objectives for the
screening program28.
The program ran from 1949 to 1953, briefly revived from
1955 to 1956 (Figures 2, 3). Screening for antibiotic-producing
cultures is only documented for the first period and work 1955–
1956 most likely involved compounds from cultures isolated
previously. Cultures of actinomycetes and in particular the
genus Streptomyces were the major source of new natural
product antibiotics during the 1940s and 1950s (Figure 1). These
compounds also constituted the focus of LEO’s program. Soil is
the main reservoir and the company outsourced the screening to
an external expert in soil microorganisms, Hans Laurits Jensen
at the State Laboratory of Plant Culture29. Most likely, H. L.
Jensen was involved due to “the problem of proper identification
(of antibiotic-producing Streptomyces cultures, my remark) is of
considerable importance to investigators who apply for process
or product patents” (Benedict, 1953). Indeed, as described for
the American company Pfizer, “each species was investigated and
registered by botanists, whose scientific discipline included the
study of soil microorganisms” (Daemmrich, 2009).
The screening by Jensen used target bacteria with low
pathogenic potential. The biological control laboratory at LEO
also conducted initial screenings using B. subtilis, E. coli, Sarcina
sp., S. aureus, and the fungus C. albicans as target cultures.
Finally, the bacteriological research laboratory used a target
panel of 10–15 pathogenic microorganisms. Tests were done on
agar media at Jensen’s laboratory and in liquid media at the
bacteriological department at LEO leading to different results.
For this reason, LEO retested isolates for inhibition of bacterial
pathogens and the bacteriological department switched to agar
media to determine antimicrobial activity. However, many target
microorganisms demanded specific growth conditions and could
27Letter to Benedict, April 20th, 1949. Letters from LEO to culture collections, see
Supplementary Table S1.
28Feed supplement: Letter from LEO to a Danish company November 29th, 1950.
Cancer treatment: Note November 18th, 1954 on Actinomycin C and a report on
microbial chemotherapy, September 1st, 1953. Anti-viral effects: Procedure March
6th, 1954. Veterinary applications: Numerous documents.
29Report November 18th 1950 on experimental activity in pilot plant of
the penicillin factory. Note December 6th 1951 on antibiotic research from
Bacteriological Department. Note December 7th 1951 describing current
procedure for antibiotic screening and suggestion for changes of procedure.
Meeting summary December 13th 1951 on guidelines regarding antibiotic
research.
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not be cultured together on agar plates. Further, safety concerns
limited the extent of work on pathogenic cultures. This situation
resulted already in 1951 in a bottleneck, as it was not possible
to test weekly three antibiotic-producing cultures on 20 different
media as initially suggested. This limited the number of possible
target strains. Criteria for their selection included an important
pathogenic role, easy to culture and not too dangerous to work
with. If a sample gave a positive result for a selected bacterium,
other species would be tested30. This made it important that target
strains used for screenings were representative of the clinical
microorganisms of interest. This experience was not unique
to LEO, and a contemporary “lesson learned . . .(was) . . . that
the substances one finds using a given screening method are
not necessarily most effective against the target of the screen”
(Lechevalier, 1980). The aim of finding the best target strain was
a forerunner to standardize antibiotic testing although the major
push in that regard came from the determination of antibiotic
resistance (Gradmann, 2013).
Perhaps due to this bottleneck the company limited further
work in 1952 to compounds already selected. One or two
chemists from the hormone factory at LEO worked up to 1956
on 32 antibiotics that had passed the initial tests with four
compounds analyzed in 1950, three in 1951, 13 in 1952–1953
and 12 in 1955–195631. The chemists, at the same time also
worked on heparin and adrenocorticotropic hormone (Schrøder
et al., 2008)32. This illustrates the expertise at the company
to characterize biological compounds, a line of work that
differed from the synthetic chemistry done at the chemical
research laboratory. Analyses included determinations of melting
point, optical rotation, UV absorption, toxicity, antimicrobial
spectrum and animal therapy experiments (Supplementary
Table S2)33. In nine cases, the compounds were compared
to known antibiotics by chromatographic analysis, a method
commonly used at the time for this purpose (McGraw, 1976).
At the end, all compounds were shelved, typically due to they
were either known already, exhibited toxicity or some target
organisms were resistant, all well-known obstacles in antibiotic
screening programs.
The natural product antibiotic program involved several
laboratories and departments within the company. The
bacteriological department tested the inhibitory activity of
antibiotic-producing cultures toward pathogenic target bacteria.
The research laboratory at the penicillin factory optimized
30Meeting summary August 27th, 1951. Changed procedure for selection of
antibiotic-producing cultures, December 5th, 1951. Note on collaboration between
Biological Research Laboratory and Bacteriological Research Laboratory March
6th, 1952. Suggestion August 8th, 1952 for changes in guidelines regarding
antibiotic research. LEO also analyzed an unknown number of their own soil
samples (Undated document). See also note 26.
31Laboratory book 1 October 12th, 1951 to November 26th, 1952. Laboratory book
2, see note 21. Note December 6th, 1951.
32Also documented by the monthly time allocation on subjects the chemists were
working on.
33Meeting summary on comparing an unknown antibiotic with patulin, October
1st, 1951. Description December 20th, 1952 of testing an antibiotic. Note
December 6th, 1951 on antibiotic research from Bacteriological Department.
Overview October 20th, 1952 on test results for six new antibiotics. Note December
20th, 1952 on purification of an antibiotic and testing antimicrobial spectrum.
Laboratory book 1 and Laboratory book 2. See also Supplementary Table S2.
conditions for antibiotic production by testing different media,
mutagenesis of producer strain or adding antibiotic precursors to
the growth medium34. Chemists at the hormone factory purified
and performed physicochemical analyses of antibiotics. Finally,
the biological control laboratory at the penicillin factory carried
out testing inhibitory activity toward mostly non-pathogenic
bacteria and the biological department was involved in toxicity
assays35. In conclusion, the company expertise included
microbiological and biotechnological aspects, purification of
organic compounds and competences in analytic and synthetic
chemistry. This situation differed from the one described for
Bayer where what was described as Bayer’s drug development
department did not employ a single microbiologist in the 1950s
(Gradmann, 2016).
THE CASE FOR SERENDIPITY:
DISCOVERY OF FUSIDIC ACID IN 1960
The empirical nature of natural product antibiotic search
programs in the late 1940s and early 1950s is illustrated by
this example: “It was a silly-simple project: collect soil samples,
plate them out, isolate actinomycetes, test them for antibiotic
activity against non-pathogenic strains of mycobacteria and hope
you find something that will be active against the pathogenic
strains” [Lechevalier (1980), recalling his research in the late
1940s in Salman Waksman’s laboratory]. Further, the high
probability of rediscovering known compounds made large
search programs necessary. Actinomycetes cultures producing
the most commonly encountered antibiotic, streptothricin are
found with a frequency of around 10% in nature, a number
similar to the frequency of 12.5% of microorganisms with
antimicrobial activity found by Eli Lilly from 1949 to 1959
(Table 3; Baltz, 2007). Actinomycetes cultures producing other
antibiotics are found with lower frequencies and correspondingly
larger screenings are necessary for their discovery (Baltz,
2007,2008). For Eli Lilly the overall number of strains screened
34Report November 18th, 1950 on experimental activity in the pilot plant of the
penicillin factory.
35Note March 6th, 1952 regarding standardizing the target bacterial panel. Several
documents refer to bacteriological and toxicity assays done by the Biological
Department.
TABLE 3 | Comparison of natural product antibiotic screenings by Eli Lilly and
LEO 1949–1959a.
Number of Eli Lilly LEO
Soil samples 10,000 No data










aData for Eli Lilly from Kahn (1975), and for LEO from this study.
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over three decades amounted to 1,000,000 isolates and for Abbott
laboratories about 400,000 isolated by the mid-1990s (Katz and
Baltz, 2016). The number of isolates with antimicrobial activity
obtained by LEO was nearly a 100-fold lower, compared to
Eli Lilly (Table 3). There is no information on the number
of environmental (soil) samples examined by LEO and the
collaborator at the State Laboratory of Plant Culture but it most
certainly was much lower than the 10,000 samples examined by
Eli Lilly 1949–1959 and 100,000 samples examined by Pfizer in
the late 1940s (Kahn, 1975; Greenwood, 2008; Daemmrich, 2009).
The outcome of the screenings by Pfizer and Eli Lilly was just
one (oxytetracycline) and three (two of them erythromycin and
vancomycin) antibiotics on the market and it is not surprising
that LEOs limited efforts in the first half of the 1950s led to
nothing. If the screening at LEO is compared with the work by
two other small research units at the time, the ETH laboratory
in Switzerland and the laboratory run by Salman Waksman at
Rutgers University, the negative outcomes for LEO and the ETH
were similar but opposed to the Waksman laboratory. The latter,
however, initiated their work much earlier resulting in discoveries
of several actinomycetes antibiotics, four of which found practical
applications: Actinomycin (cancer), streptomycin (tuberculosis),
neomycin (e.g., tuberculosis), and candicidin (anti-fungal). In all
three cases actinomycetes antibiotics constituted a major focus
but most of the low hanging fruits were gone by the time LEO
and ETH initiated their work (Ettlinger, 1980; Lechevalier, 1980).
It is of interest that regarding natural product antibiotics
LEO looked during the early 1950s for opportunities when
possible. In one example, the company participated in an
investigation that was a forerunner to the open innovation
concept; a concept that recently had become popular among
pharmaceutical companies including LEO Pharma (Nilsson and
Felding, 2015). A confidential letter from 1951 describes the
potential collaboration between the company and a medical
doctor who had found an actinomycetes culture producing an
antibiotic with no toxicity but with relatively strong in vivo
inhibitory activity toward Mycobacterium tuberculosis using
guinea pigs as an experimental model. The compound had
not been isolated and therefore its chemical composition and
structure was unknown. There were indications that it did not
resemble known antibiotics used chemotherapeutically at the
time. The company would aim at reproducing these findings
and in case of an affirmative result, would conduct further
investigations to explore possibilities for manufacturing the
antibiotic in quantities for the use of chemotherapeutic treatment
of human tuberculosis patients. In case of a positive outcome, the
doctor was interested in LEO producing the compound on basis
of a license36. Most likely, results did not support this prospect
and no other documents in the archive refer to this case.
Another example of the search for the potential chance
discovery was the testing of an antibiotic-producing culture
accidentally obtained from the lab environment, however again
without result37.
36Meeting summary December 7th, 1951.
37Document January 24th, 1952.
Success finally arrived with the discovery of fusidic acid
in 1960, a serendipitous result of the work on semisynthetic
β-lactams around this time (Rolinson, 1998; Kingston, 2000;
Bud, 2007; Greenwood, 2008). This approach used mold-
derived penicillin-degrading enzymes to obtain a penicillin core
compound, 6-aminopenicillanic acid as a basic building block.
As the scientists went through the catalog on mold cultures
from a Dutch collection, they found a Fusidium coccineum (now
Acremonium fusidioides) strain, an organism they had not heard
about before. They decided to “very unscientifically to buy it –
just because of the similarity of the name with Fusarium” –
organisms they already used (quotation from Gotfredsen, 1997;
the event is also described by Greenwood, 2008). Testing the
strain for antibiotic production resulted in the discovery of
fusidic acid, an anti-staphylococcal compound that has remained
an important source of revenue for LEO (Schrøder, 2005;
Schrøder et al., 2008; Fernandes, 2016). The discovery was timely
due to contemporary issues in hospitals with antibiotic-resistant
S. aureus (Schrøder et al., 2008).
It is instructive that LEO’s first real successful hit came when
they examined the antibiotic potential of a genus of molds not
tested previously, although related compounds, helvolic acid
and cephalosporin P1 produced by other genera of molds were
discovered much earlier, in 1943 and 1951 (Ritchie et al., 1951;
Chain et al., 1953; Burton et al., 1956). Searching for new
antibiotics among taxonomic groups of poorly characterized
microorganisms remains one of the strategies for screenings
programs today, with the discovery of teixobactin as one of many
examples (Peláez, 2006; Aminov, 2010, 2017; Lewis, 2013, 2015;
Genilloud, 2014; Ling et al., 2015). Serendipity did, however not
guarantee any follow-up discoveries, and further searches by LEO
for antibiotic-producing molds were not successful, as described
by a scientist that took part in the work (A. Kjøller, personal
communication). Since the strain that produced fusidic acid was
isolated from monkey excrement in Japan, similar excrements
from the local zoological garden in Copenhagen were a source of
investigation in addition to soil samples from various locations in
Denmark and abroad. Within a couple of years testing included
thousands of strains but this led only to compounds that were
either known already or too toxic. Actinomycetes antibiotics did
not constitute a focus for this screening program. LEO continued
work on antimicrobial compounds in the late 1960s and the
1970s and reported a few novel natural product compounds from
cultures of Streptomyces or molds but no further R&D appear to
have taken place (Gotfredsen and Vangedal, 1965; Von Daehne
et al., 1969; Gotfredsen et al., 1970). The company eventually lost
interest in antibiotics during the 1980s although fusidic acid is
still manufactured today.
CONCLUSION
This study explores the variety of strategies employed during
the 1940s and 1950s for finding new natural, semisynthetic and
synthetic antibiotic compounds. It is of interest, that LEO was
a pharmaceutical company of relatively small size. Further, the
owner from 1940 and until 1986, Knud Abildgaard aimed at
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rapidly securing marketable results from research. This offered
less opportunity for larger strategic efforts, as opposed to
numerous smaller projects. Although Abildgaard did not have
a pharmaceutical or chemical background, he had, however,
obtained an extensive amount of pharmaceutical knowledge
(Schrøder, 2005; Schrøder et al., 2008). Taken together, these
circumstances allowed LEO to maintain flexibility in strategies for
R&D of antimicrobial compounds.
Research on synthetic antibiotics and salts and esters of
penicillin benefited from the collaboration with K. A. Jensen as
he tested antimicrobial activities, organized clinical trials and
gave essential input as a consultant. He and other consultants
also participated in regular meetings with the management of
LEO. These meetings concluded by dinners that also served as
incubators for professional interactions and even friendship and
thereby fulfilling a role as a basis of knowledge and insights
that served LEO well in their research (Jensen, 1971). The
importance of this type of “privileged collaborative relations with
clinical researchers” agrees well with the conclusions reached for
Rhône-Poulenc’s research on anti-cancer drugs during the 1970s
(Quirke, 2014).
Interestingly, the work on natural product antibiotics involved
a collaborator, H. A. Jensen serving only a supportive role. This
situation was not too different from the research that led to the
discovery of chloramphenicol. “In 1943, no doubt alert to the
work that Waksman was doing at Rutgers, but not yet wishing
to commit company resources to an uncertain field of study,
Parke, Davis and Co. in Detroit provided the funds for Paul
Burkholder, Eaton professor of botany at Yale to screen samples
of soil for micro-organisms producing substances with antibiotic
activity” (Greenwood, 2008, p. 219). Similarly, LEO took a careful
approach as at least the chemical analyses of these compounds
constituted a relatively limited amount of overall research time
(Table 2 and Figure 2).
In overall, the work by LEO came some way to meet the
challenges at the time for finding new antibiotics. These included
a need to be more precise in targeting the pathogens. This was
the objective with the screening for antimicrobial compounds
toward M. tuberculosis, and the search for compounds with a
localized activity, e.g., an improved lung affinity. Further, the
search included compounds with effect on antibiotic-resistant
targets and/or on virulence rather than survival. In addition, the
discovery of fusidic acid was a reward for testing microorganisms
not previously well explored. Finally, there was an example
of open innovation, a management mechanism that supports
discoveries by searching outside the search parameters set by the
company. All of these approaches are also in one way or another
in play in the antibiotic discovery process today (Peláez, 2006;
Baltz, 2008; Aminov, 2010, 2017; Rasko and Sperandio, 2010;
Lewis, 2013, 2015; Genilloud, 2014).
AUTHOR CONTRIBUTIONS
JL designed the study, performed the research, and
wrote the manuscript.
ACKNOWLEDGMENTS
I thank Arne Bo Mandøe, head of LEO Pharma Historical
Archives and Museum LEO Foundation, Industriparken 55, DK-
2750 Ballerup, Denmark for allowing access to the archives and
generous help, Dr. Annelise Kjøller, Department of Biology,
University of Copenhagen, for information on the discovery of
fusidic acid, Dr. Martin A. Hansen for information on bacterial
strains at LEO Pharma, Professor, Dr. Niels Høiby, Department
of Immunology and Microbiology, University of Copenhagen,
for information on K. A. Jensen, Professor Dr. Troels Lillebaek
at the State Serum Institute, Copenhagen for providing access to
the SSI journal archive and Associate Professor, Dr. Jan Pedersen
at the Saxo Institute, University of Copenhagen for valuable
comments on an initial version of the manuscript. Finally, I
would like to thank two reviewers for several essential comments
and suggestions. This research did not receive any specific grant
from funding agencies in the public, commercial, or not-for-
profit sectors.
SUPPLEMENTARY MATERIAL




Abouelhassan, Y., Garrison, A. T., Yang, H., Chávez-Riveros, A., Burch, G. M., and
Huigens, R. W. (2019). Recent progress in natural-product-inspired programs
aimed to address antibiotic resistance and tolerance. J. Med. Chem. 62, 7618–
7642. doi: 10.1021/acs.jmedchem.9b00370
Aminov, R. (2017). History of antimicrobial drug discovery: major classes and
health impact. Biochem. Pharmacol. 133, 4–19. doi: 10.1016/j.bcp.2016.10.001
Aminov, R. I. (2010). A brief history of the antibiotic era: lessons learned and
challenges for the future. Front. Microbiol. 1:134. doi: 10.3389/fmib.2010.00134
Anon. (1958). US Federal Trade Commission, Economic Report on Antibiotics
Manufacture. Washington, DC: U.S. Government Printing Office.
Baltz, R. H. (2007). Antimicrobials from actinomycetes: back to the future. Microbe
2, 125–131.
Baltz, R. H. (2008). Renaissance in antibacterial discovery from actinomycetes.
Curr. Opin. Pharmacol. 8, 557–563. doi: 10.1016/j.coph.2008.04.008
Benedict, R. G. (1953). Antibiotics produced by actinomycetes. Botan. Rev. 15,
229–314.
Bud, R. (2007). Penicillin. Triumph and Tragedy. Oxford: Oxford University Press.
Burton, H. S., Abraham, E. P., and Cardwell, H. M. E. (1956). Cephalosporin
P1 and helvolic acid. Biochem. J. 62, 171–176. doi: 10.1042/bj0
620171
Chain, E., Florey, H. W., Jennings, M. A., and Williams, T. I. (1953). Helvolic acid,
an antibiotic produced by Aspergillus fumigatus. mut. helvola Yuill. Brit. J. Exp.
Pathol. 24, 108–119.
Cozzoli, D. (2014). Penicillin and the European response to post-war American
hegemony: the case of LEO-penicillin. Hist. Technol. 30, 83–103. doi: 10.1080/
07341512.2014.902232
Frontiers in Microbiology | www.frontiersin.org 10 June 2020 | Volume 11 | Article 976
fmicb-11-00976 June 10, 2020 Time: 21:55 # 11
Leisner Screening for Antimicrobial Compounds
Daemmrich, A. (2009). Synthesis by microbes or chemists? Pharmaceutical
research and manufacturing in the antibiotic era. Hist. Technol. 25, 237–256.
doi: 10.1080/07341510903083237
Espersen, E. (1949). Morphological studies of the normal growth of a human
tubercle strain, and the effects of some antibacterial substances on same. Acta
Pathol. Scand. 26, 178–204. doi: 10.1111/j.1699-0463.1949.tb03154.x doi: 10.
1111/j.1699-0463.1949.tb03154.x
Ettlinger, L. (1980). “Wartime research on penicillin in Switzerland and antibiotic
screening,” in The History of Antibiotics. A Symposium, ed. J. Parascandola
(Madison, WI: American Institute of the History of Pharmacy), 57–67.
Fernandes, P. (2016). Fusidic acid: a bacterial elongation factor inhibitor
for the oral treatment of acute and chronic staphylococcal infections.
Cold Spring Harb. Perspect. Med. 6:a025437. doi: 10.1101/cshperspect.
a025437
Fox, G. J., Schaaf, H. S., Mandalakas, A., Chiappini, E., Zumla, A., and Marais,
B. J. (2017). Preventing the spread of multidrug-resistant tuberculosis and
protecting contacts of infectious cases. Clin. Microbiol. Infect. 23, 147–153.
doi: 10.1016/j.cmi.2016.08.024
Frederiksen, E., Jensen, K. A., Morch, P., and Tybring, L. (1957). Tebamin:
a derivative of p-aminosalicylic acid; blood levels, absorption and
excretion following oral administration. Acta Pharmacol. Toxicol.
14, 58–66. doi: 10.1111/j.1600-0773.1957.tb01142.x
Genilloud, O. (2014). The re-emerging role of microbial natural products in
antibiotic discovery. Ant. Leeuw. 106, 173–178.
Gotfredsen, W. O. (1991). Penicillinet 50 år. En beretning om en af
medicinhistoriens store opdagelser. Løvens Litter. Inform. 23, 149–165.
Gotfredsen, W. O. (1997). Om Opdagelsen og Udviklingen af Fucidin. Ballerup:
Løvens Kemiske Fabrik.
Gotfredsen, W. O., and Vangedal, S. (1965). Trichodermin, a new sesquiterpene
antibiotic. Acta Chem. Scand. 19, 1088–1102. doi: 10.3891/acta.chem.scand.19-
1088
Gotfredsen, W. O., Vangedal, S., and Thomas, D. W. (1970). Cycloheptamycin,
a new peptide antibiotic. Structure determination by mass spectrometry.
Tetrahedron 26, 4931–4946. doi: 10.1016/s0040-4020(01)93145-x
Gotfredsen, W. O. (1999a). OmOpdagelsen og Udviklingen af Pondocillin. Ballerup:
Løvens Kemiske Fabrik.
Gotfredsen, W. O. (1999b). Om Opdagelsen og Udviklingen af Sultamicillin.
Ballerup: Løvens Kemiske Fabrik.
Gradmann, C. (2013). Sensitive matters: the world health organisation and
antibiotic resistance testing, 1945-1975. Soc. Hist. Med. 26, 555–574. doi: 10.
1093/shm/hkt018
Gradmann, C. (2016). Re-inventing infectious disease: antibiotic resistance and
drug development at the Bayer company 1945-1980. Med. Hist. 60, 155–180.
doi: 10.1017/mdh.2016.2
Greenwood, D. (2008). Antimicrobial Drugs. Chronicle of a Twentieth Century
Medical Triumph. Oxford: Oxford University Press.
Høiby, N. (2000). “Der er to slags forskere, de positive og de negative,” inMin Bedste
Lærer, ed. J. Riis (Copenhagen: Gyldendalske Boghandel, Nordisk Forlag A/S
Copenhagen), 116–128.
Høiby, N. (2016). Kai Adolf Jensen, professor i almindelig patologi. Bibliotek for
Læger 208, 344–361.
Jain, S. K., Lamichhane, G., Nimmagadda, S., Pomper, M. G., and Bishai, W. R.
(2008). Antibiotic treatment of tuberculosis: old problems, new solutions.
Microbe 3, 285–292. doi: 10.1128/microbe.3.285.1
Jensen, K. (2002). Bekæmpelse af Infektionssygdomme – Statens Serum Institut
1902-2002. Copenhagen: Nyt Nordisk Forlag Arnold Busck.
Jensen, K. A. (1971). Fabrikejer Knud Abildgaard 70 år. Medicinsk Forum 23/24,
16–19.
Jensen, K. A., Dragsted, P. J., Kiaer, I., Nielsen, E. J., and Frederiksen,
E. (1951). Leocillin (Benzylpenicillin-β-diethylaminoethylesterhydrochloride).
Acta Pathol. Microbiol. Scand. 28, 407–414.
Kahn, E. J. Jr. (1975). All in a Century. The First 100 Years of Eli Lilly and Company.
Indianapolis, IN: Eli Lilly and Company.
Kane, J. H., Finlay, A. C., and Sobin, B. A. (1950). Antimicrobial agents from
natural sources. Ann. N.Y. Acad. Sci. 53, 226–228.
Katz, L., and Baltz, R. H. (2016). Natural product discovery: past, present and
future. J. Ind. Microbiol. Biotechnol. 43, 155–176.
Kavanagh, F., Hervey, A., and Robbins, W. J. (1951). Antibiotic substances from
Basidiomycetes: VII. Pleurotus mutilus (FR.) sacc. and Pleurotus passeckerianus
Pilat. Proc. Natl. Acad. Sci. U.S.A. 37, 570–574. doi: 10.1073/pnas.37.9.570
Keshavjee, S., and Farmer, P. E. (2012). Tuberculosis, drug resistance, and the
history of modern medicine. N. Engl. J. Med. 367, 931–936. doi: 10.1056/
NEJMra1205429
Kingston, W. (2000). Antibiotics, invention and innovation. Res. Policy 29, 679–
710. doi: 10.1016/s0048-7333(99)00045-1
Lechevalier, H. A. (1980). “The search for antibiotics at Rutgers university,” in
The History of Antibiotics. A Symposium, ed. J. Parascandola (Madison, WI:
American Institute of the History of Pharmacy), 113–123.
Lewis, K. (2013). Platforms for antibiotic discovery. Nat. Rev. Drug Dis. 12,
371–387. doi: 10.1038/nrd3975
Lewis, K. (2015). Challenges of antibiotic discovery. Microbe Wash. D. C. 10,
363–369. doi: 10.1128/microbe.10.363.1
Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P.,
et al. (2015). A new antibiotic kills pathogens without detectable resistance.
Nature 517, 455–459. doi: 10.1038/nature14303
Loldrup, H.-O. (2014). Dansk Medicin. Historien om de Danske Medicinfabrikker.
Copenhagen: Loldrups forlag.
McGraw, D. J. (1976). The Antibiotic Discovery Era (1940-1960): Vancomycin as an
Example of the Era. Ph.D. thesis. Oregon State University, U.S.A, Eugene, OR.
Nilsson, N., and Felding, J. (2015). Open innovation platform to boost
pharmaceutical collaborations: evaluating external compounds for desired
biological activity. Future Med. Chem. 7, 1853–1859. doi: 10.4155/fmc.15.122
Peláez, F. (2006). The historical delivery of antibiotics from microbial natural
products – Can history repeat? Biochem. Pharmacol. 71, 981–990. doi: 10.1016/
j.bcp.2005.10.010
Quinn, R. (2009). Broader Spectrum: A History of Antibiotic R&D. Ph.D.
Dissertation. University of Urbana-Champaign, Urbana, IL.
Quirke, V. (2014). Targeting the American market for medicines, ca. 1950s-1970s:
ICI and Rhône-Poulenc compared. Bull. Hist. Med. 88, 654–696. doi: 10.1353/
bhm.2014.0075
Raper, K. B. (1952). A decade of antibiotics in America. Mycologia 44, 1–59.
doi: 10.1080/00275514.1952.12024170
Rasko, D. A., and Sperandio, V. (2010). Anti-virulence strategies to combat
bacteria-mediated disease. Nat. Rev. Drug discov. 9, 117–128. doi: 10.1038/
nrd3013
Ritchie, A. C., Smith, N., and Florey, H. W. (1951). Some biological properties
of cephalosporin P1. Br. J. Pharmacol. 6:430. doi: 10.1111/j.1476-5381.1951.
tb00653.x
Rolinson, G. N. (1998). Forty years of β-lactam research. J. Antimicrob. Chemother.
41, 589–603. doi: 10.1093/jac/41.6.589
Schrøder, P. (2005). Fra løveapotekets kemiske fabrik til LEO Pharma A/S.Theriaca
36, 27–118.
Schrøder, P., Kirkegaard, H., and Holmstad, D. (2008). Leo Pharma 1908-2008.
Ballerup: LEO Pharma.
Silver, L. L. (2011). Challenges of antibacterial discovery. Clin. Microbiol Rev. 24,
71–109.
Spellberg, B. (2014). The future of antibiotics. Critical Care 18:228.
Tanner, L., Denti, P., Wiesner, L., and Warner, D. F. (2018). Drug permeation
and metabolism in Mycobacterium tuberculosis: prioritising local exposure as
essential criterion in new TB drug development. IUBMB Life 70, 926–937.
doi: 10.1002/iub.1866
Temin, P. (1979). Technology, regulation, and market structure in the modern
pharmaceutical industry. Bell J. Econ. 10, 429–446.
Theuretzbacher, U., and Piddock, L. J. V. (2019). Non-traditional antibacterial
therapeutic options and challenges. Cell Host Micr. 26, 61–72. doi: 10.1016/j.
chom.2019.06.004
Tjørnelund, H. (2016). Da det Frelsende mug Kom til København. En Videnskabs og
Teknologihistorisk Afhandling om Udviklingen af den Første Danske Penicillin
Fra 1942 Til 1959. Ph.D. Thesis, Roskilde University, Roskilde.
Tørning, K., Jensen, K. A., and Kiaer, I. (1958). Clinical Studies on Tebamin. Acta
Tuberc. Scand. 35, 87–100.
Umezawa, H., Kondo, S., Meda, K., Okami, Y., Okada, T., and Takeda, K. (1967).
Index of Antibiotics From Actinomycetes. State College, PA: University Park
Press.
Frontiers in Microbiology | www.frontiersin.org 11 June 2020 | Volume 11 | Article 976
fmicb-11-00976 June 10, 2020 Time: 21:55 # 12
Leisner Screening for Antimicrobial Compounds
Von Daehne, W., Gotfredsen, W. O., Tybring, L., and Schaumburg, K. (1969). New
antibiotics containing the 1,2-dithiolo[4,3-b]pyrrole ring system. J. Antibio. 22,
233–236. doi: 10.7164/antibiotics.22.233
Waksman, S. A., and Lechevalier, H. A. (1949). Neomycin, a new antibiotic active
against streptomycin-resistant bacteria, including tuberculosis organisms.
Science 109, 305–307. doi: 10.1126/science.109.2830.305
Waksman, S. A., and Lechevalier, H. A. (1953).Actinomycetes and Their Antibiotics.
Baltimore: The Williams & Wilkins Company.
Wright, G. D. (2014). Something old, something new: revisiting natural products
in antibiotic drug discovery. Can. J. Microbiol. 60, 147–154. doi: 10.1139/cjm-
2014-0063
Wright, P. M., Seiple, I. B., and Myers, A. G. (2014). The evolving role
of chemical synthesis in antibacterial drug discovery. Angew. Chem. Int.
Ed. Eng. 53, 8840–8869. doi: 10.1002/anie.201310843doi: 10.1002/anie.20
1310843
Conflict of Interest: The author declares that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2020 Leisner. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 12 June 2020 | Volume 11 | Article 976
